Letters to the Editor

Dexamethasone is associated with reduced frequency and intensity of cytokine release syndrome compared with alternative corticosteroid regimens as premedication for glofitamab in patients with relapsed / refractory large B-cell lymphoma

Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY
Rigshospitalet and University of Copenhagen, Copenhagen, Denmark
Humanitas University and IRCCS Humanitas Research Hospital, Milan
Hôpital Claude Huriez and CHU de Lille, Lille
Peter MacCallum Cancer Centre, Royal Melbourne Hospital and The University of Melbourne, Melbourne, VIC
CHU de Montpellier, Montpellier
Allegheny Health Network, Pittsburgh, PA
Ospedale Santa Maria delle Croci, Ravenna
Hospital Universitario 12 de Octubre, Spanish National Cancer Research Center (CNIO), Complutense University Madrid, imas12, Madrid
Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO
Hospital del Mar, Passeig Maritim, Barcelona
Tisch Cancer Institute, New York, NY
University of Helsinki and Helsinki University Hospital Comprehensive Cancer Center, Helsinki
F. Hoffmann-La Roche Ltd, Basel
F. Hoffmann-La Roche Ltd, Basel
Roche Products Ltd, Welwyn Garden City
Genentech, Inc., South San Francisco, CA, USA and
F. Hoffmann-La Roche Ltd, Basel
Hôpital Lyon Sud, Hospices Civils de Lyon, Lyon
Haematologica Early view Nov 28, 2024 https://doi.org/10.3324/haematol.2024.286257